Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -10.04%32 Debt-to-EBITDA is -0.01 as of Mar. 2026. GuruFocus rates BJDX with a GF Score™ of 32/100. Among 467 Medical Devices & Instruments companies, Bluejay Diagnostics ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bluejay Diagnostics's Debt-to-EBITDA or its related term are showing as below:
BJDX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.08 Med: -0.05 Max: -0.01
Current: -0.01
During the past 7 years, the highest Debt-to-EBITDA Ratio of Bluejay Diagnostics was -0.01. The lowest was -1.08. And the median was -0.05.
BJDX's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs BJDX: -0.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bluejay Diagnostics Debt-to-EBITDA Related Terms
Bluejay Diagnostics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs ALURD, VTAK, AMIX: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bluejay Diagnostics (BJDX) has a Debt-to-EBITDA of -0.01 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bluejay Diagnostics. According to the industry distribution chart, Bluejay Diagnostics ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Bluejay Diagnostics' Debt-to-EBITDA too high?
Bluejay Diagnostics' current Debt-to-EBITDA is -0.01. Based on the distribution chart, Bluejay Diagnostics ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Debt-to-EBITDA compare to ALURD and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Bluejay Diagnostics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bluejay Diagnostics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current Debt-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Debt-to-EBITDA of -0.01. The current Debt-to-EBITDA is -0.01. Bluejay Diagnostics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Debt-to-EBITDA is -0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
32GF Score
Get the complete analysis for BJDX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
